Our product assessments recognize the diversity of our customer base. For Cetaphil® alone we have conducted over 770 clinical trials with more than 21,000 participants since 2019. And Galderma’s Global Sensitive Skincare Faculty’s 2023 collaboration with the George Washington University included more than 10,000 participants across seven countries and five continents. It was the most extensive global epidemiological study assessing and characterizing sensitive skin ever.
Ensuring product availability and access is also a top priority. We focus on supporting projects for people suffering from skin conditions, such as prurigo nodularis, a debilitating chronic condition characterized by intense itch. Nemolizumab, an investigational monoclonal antibody, is in clinical development for treating prurigo nodularis and has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA).
In February 2024, the U.S. FDA accepted the Biologics License Applications for nemolizumab for the treatment of prurigo nodularis, and for adolescents and adults with moderate to severe atopic dermatitis. Additionally, it granted Priority Review for the treatment of prurigo nodularis.
In addition to offering a diverse portfolio of flagship brands, we actively contribute to community-building initiatives. For over a decade, we've supported Camp Wonder, providing children with chronic skin conditions the chance to escape their everyday lives – and just be kids. Through product donations, employee volunteering, and financial contributions, we're proud to make a positive impact on their lives.
